Abstract
The increasing life expectancy leads to more older adults suffering from infectious diseases. Vaccines are available against diverse infections such as influenza, pneumococcal disease, herpes zoster and tetanus. However, vaccine acceptance is crucial for optimal preventive effect. The objective of the study is to perform a cross-country analysis of the perceptions and decision-making behaviour of older adults regarding vaccinations and their information needs. Focus groups with older adults were conducted in four countries: France, Hungary, Italy and the Netherlands. Data were analysed using thematic analysis. Demographic characteristics of participants were gathered with a questionnaire. Influenza and tetanus vaccines were commonly known, as was the disease influenza. On the contrary, the awareness of the vaccines against pneumococcal disease and herpes zoster were low. Participants also expressed a need for more information on vaccines, such as possible side effects, contra-indications and duration of protection, emphasizing that information is a condition for decision-making on vaccination. General practitioners were found to be the most important in information provision on vaccines. Perceptions on vaccines, such as effectiveness, side effects and safety, as well as perceptions on infectious diseases, such as severity, susceptibility and experiencing an infectious disease, played a role in the decision-making of older adults on vaccines. More awareness of the information needs among older adults with regard to vaccines should be raised among general practitioners and other healthcare providers. This requires appropriate knowledge about the vaccines among healthcare providers as well as communication skills to meet the information needs of older adults.
Original language | English |
---|---|
Pages (from-to) | 871-887 |
Number of pages | 17 |
Journal | GeroScience |
Volume | 45 |
Issue number | 2 |
Early online date | 21 Nov 2022 |
DOIs | |
Publication status | Published - Apr 2023 |
Bibliographical note
Funding Information:The VITAL project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806776. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This article reflects only the author’s views and neither the IMI2 JU nor the Commission is liable for any use that may be made of the information contained herein.
Publisher Copyright:
© 2022, The Author(s).
Funding
The VITAL project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806776. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This article reflects only the author’s views and neither the IMI2 JU nor the Commission is liable for any use that may be made of the information contained herein.
Funders | Funder number |
---|---|
Horizon 2020 Framework Programme | |
European Federation of Pharmaceutical Industries and Associations | |
Innovative Medicines Initiative | 806776 |
Innovative Medicines Initiative |
Keywords
- Decision-making
- Infectious diseases
- Older adults
- Qualitative
- Vaccines